Zang Jingzhe, Wang Tingting, Zhang Fei, Li Lifeng, Yu Zhidan, Sun Meng, Liu Kangbo, Zhang Xianwei, Wang Peng, Zhang Wancun
Health Commission of Henan Province Key Laboratory for Precision Diagnosis and Treatment of Pediatric Tumor, Henan International Joint Laboratory for Prevention and Treatment of Pediatric Disease, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, China.
Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
ACS Sens. 2025 Aug 22;10(8):6142-6153. doi: 10.1021/acssensors.5c01826. Epub 2025 Aug 7.
The abnormal localization of mitochondrial human apurinic/apyrimidinic endonuclease 1 (APE1) is closely associated with tumor progression, prognosis, and drug resistance. While APE1 can localize to both the cytoplasm and nucleus as well as mitochondria. Consequently, the design of approaches with controllable localization for imaging of mitochondrial APE1 is particularly challenging. Therefore, a cyclic amplified programmable allosteric DNA biosensor (C-AP-tFNA) was developed for APE1-triggered spatially controlled mitochondrial molecular imaging. First, the interaction between the S5-S6 region of C-AP-tFNA and the mitochondria-specific localization of cytochrome c (cyt c) induces a conformational change from S5-S6 to S6, thereby enabling the activation of the AP site in S6 for cleavage by mitochondrial APE1. Second, the conformationally altered S6 can be cyclically activated and cleaved by mitochondrial APE1, leading to further configurational changes in S6 and the generation of fluorescent signals. Therefore, C-AP-tFNA enables highly sensitive and specific detection of mitochondrial APE1 in an AND-gated and cyclic amplification manner. The experimental results of this study demonstrated that C-AP-tFNA can achieve high specificity imaging of mitochondrial APE1 in tumor and inflammatory cells with high sensitivity. More importantly, C-AP-tFNA can monitor neuroblastoma drug resistance , providing a novel and effective approach for monitoring neuroblastoma drug resistance.
线粒体人脱嘌呤/脱嘧啶内切酶1(APE1)的异常定位与肿瘤进展、预后及耐药性密切相关。虽然APE1可定位于细胞质、细胞核以及线粒体。因此,设计可控制定位的方法用于线粒体APE1成像极具挑战性。为此,开发了一种环状扩增可编程变构DNA生物传感器(C-AP-tFNA)用于由APE1触发的空间可控线粒体分子成像。首先,C-AP-tFNA的S5-S6区域与细胞色素c(cyt c)的线粒体特异性定位之间的相互作用诱导了从S5-S6到S6的构象变化,从而使S6中的AP位点被线粒体APE1切割而激活。其次,构象改变的S6可被线粒体APE1循环激活和切割,导致S6进一步的构型变化并产生荧光信号。因此,C-AP-tFNA能够以与门控和循环放大的方式对线粒体APE1进行高度灵敏且特异的检测。本研究的实验结果表明,C-AP-tFNA能够在肿瘤细胞和炎性细胞中对线粒体APE1进行高特异性的高灵敏度成像。更重要的是,C-AP-tFNA能够监测神经母细胞瘤的耐药性,为监测神经母细胞瘤耐药性提供了一种新颖有效的方法。